Comparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patients

Determining and comparing the effectiveness of standard treatment with standard treatment plus vitamin A in the treatment of patients with covid 19

In a controlled double-blind trial, a parallel plan of 140 patients will be randomly assigned to the experimental (70 subjects) and control (70 subjects) groups and will be followed for 10 days.

70 experimental group patients in Saveh will receive vitamin A, in addition to the standard treatment recommended for COVID 19 in the national protocol. Patients with COVID-19 in the control group will receive standard national treatment and placebo. Before and after treatment, the rate of recovery in both experimental and control groups is measured. The patients will be randomly allocated to the experimental group or the control group. In this study, they will be blind: laboratory technicians and radiologists, the therapist who was responsible for prescribing the drug, receiving the sample and completing the questionnaire, and the researcher responsible for evaluating the results and analyzing Statistics on group therapy of patients.

Inclusion criteria: aged 1–75 years Exclusion criteria: Autoimmune diseases (lupus, MS, etc.), Hepatit B, C, vitamin A supplement users, pregnant and lactating women

The experimental group will receive a standard medical protocol, in addition to which vitamin A will be taken orally by 25,000 IU/day for ten days. The control group will receive the standard medical protocol and plasebo.

Clinical: body temperature, number of breaths، oxygen saturation ) and cough. Paraclinical: changes in CRP levels, and lymphocytes before and after treatment, ESR, CBC diff, CPK, LDH, blood pH,o2 sat, creatinine and LFT

At the beginning of the study, an evaluator examines the criteria for entering the study of patients, and if there are conditions for entering the study, using the table of random numbers, patients will be assigned to the experimental and control group. And this process will continue until the formation of two equal groups of 70 people.

In this study, patients, laboratory technicians, radiologists, and therapists who will be responsible for prescribing the drug, receiving the sample and completing the questionnaire, as well as the researcher responsible for evaluating the results and statistically analyzing the treatment group will blind patients. Were, and will not know the intervention group. The physicians responsible for prescribing medication will not be blind. vitamin A and placebo were purchased from the same factory and coded by the third person who is not involved in the study. the patients have received the random code by the secretariat who is not involved in the study. the patients with even numbers will receive the capsules from box A and the patients with odd numbers will receive the capsules from box B. To make a placebo, Since Zahrawi Vitamin A will be used for the experimental group, the control group will also use Zahrawi's placebo drug to make the placebo look and feel similar to the original vitamin A, but the active ingredient will be an ineffective substance.

By publishing an article

Access started on September 2020

Researchers working in academic and scientific institutions

Scientific and therapeutic

Mohamad Reza Rohani, 00989122859099, mohamadreza.rohani@yahoo.com

72 hours after a phone call or email